UNSPSC 51301701: Buclosamide

This classification denotes an antifungal agent with the molecular formula C11H14ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O52NM0A9YL, chemically known as benzamide, n-butyl-4-chloro-2-hydroxy- but generally known as buclosamide, which bears US NIH Compound Identifier 68466. European Medicines Agency schedules Buclosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05948MIG.

UNSPSC 51301701 Buclosamide, a Commodity code, shows minimal alignment between its nominal scope and recent state and local solicitation activity. The code's name suggests pharmaceutical or chemical compounds in the buclosamide family, yet the recent opportunities block contains two unrelated procurements: liquid aluminum sulfate (alum) for wastewater treatment and medical aid supplies (bandages, antiseptic sprays, pain relievers, and first aid kits). Neither product is buclosamide or a closely related chemical compound. The mismatch suggests either misclassification by issuing bodies or a code assignment error in the source data, and the code shows little relevant recent activity for the stated commodity.

The two opportunities present do span different issuing bodies and geographies. The City of Austin posted IFB 2200 CSH1061 on July 27, 2026, requesting 179,200 gallons annually of liquid aluminum sulfate at 47%-49% concentration for Austin Water's wastewater treatment facility, with bids due August 25, 2026; the procurement applies local and small business preference discounts of up to 5% and 3% respectively on qualifying bids. The City of Tampa Fire Rescue Department posted ITB 25-P-00157 on April 24, 2026, for medical aid supplies across 32 line items with an estimated annual budget of $100,000 and set-asides for City-certified Small Local Business Enterprises and Underutilized Woman and Minority Owned Business Enterprises. Texas and Florida are the only states represented in the recent record. Given the absence of buclosamide-specific opportunities and the presence of unrelated commodities, pursuit under this code is not recommended without verification of the code assignment.